Cargando…

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis

Fragile X syndrome (FXS) is the leading cause of inherited intellectual disability and autism spectrum disorder. Individuals with FXS often present with a wide range of cognitive deficits and problem behaviors. Educational, behavioral and pharmacological interventions are used to manage these and ot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luu, Skylar, Province, Haley, Berry-Kravis, Elizabeth, Hagerman, Randi, Hessl, David, Vaidya, Dhananjay, Lozano, Reymundo, Rosselot, Hilary, Erickson, Craig, Kaufmann, Walter E., Budimirovic, Dejan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563217/ https://www.ncbi.nlm.nih.gov/pubmed/32932789 http://dx.doi.org/10.3390/brainsci10090629

Ejemplares similares

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives
por: Lozano, Reymundo, et al.
Publicado: (2022)

Genomic studies in fragile X premutation carriers
por: Lozano, Reymundo, et al.
Publicado: (2014)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
por: Budimirovic, Dejan B., et al.
Publicado: (2017)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

The Impact of the COVID-19 Pandemic on School-Aged Children with Fragile X Syndrome
por: Silver, Hailey, et al.
Publicado: (2022)

Modulation of the GABAergic pathway for the treatment of fragile X syndrome
por: Lozano, Reymundo, et al.
Publicado: (2014)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Case Reports of Aortic Aneurism in Fragile X Syndrome
por: Lewis, Sivan, et al.
Publicado: (2022)

A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome
por: Ligsay, Andrew, et al.
Publicado: (2017)

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
por: Lee, Anna W., et al.
Publicado: (2018)

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome
por: Hessl, David, et al.
Publicado: (2019)

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities
por: Weber, Jayne Dixon, et al.
Publicado: (2019)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Parent and Caregiver Perspectives towards Cannabidiol as a Treatment for Fragile X Syndrome
por: Maertens, Madison, et al.
Publicado: (2022)

Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization
por: Cordeiro, Lisa, et al.
Publicado: (2010)

Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders
por: Trajković, Jelena, et al.
Publicado: (2022)

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
por: Protic, Dragana D., et al.
Publicado: (2022)

Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome
por: Farzin, Faraz, et al.
Publicado: (2011)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
por: Palumbo, Joseph M., et al.
Publicado: (2023)

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
por: Berry-Kravis, E, et al.
Publicado: (2009)

The challenges of clinical trials in fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2013)

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results
por: Youssef, Eriene A, et al.
Publicado: (2018)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
por: Budimirovic, Dejan B., et al.
Publicado: (2021)

Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries?
por: Protic, Dragana, et al.
Publicado: (2021)

Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome
por: Famula, Jessica, et al.
Publicado: (2022)

Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome
por: Reisinger, Debra L., et al.
Publicado: (2020)

Executive Function in Fragile X Syndrome: A Systematic Review
por: Schmitt, Lauren M., et al.
Publicado: (2019)

Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS)
por: Knox, Andrew, et al.
Publicado: (2012)

Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials
por: Duy, Phan Q., et al.
Publicado: (2017)

Fragile X Syndrome: Recent Research Updates toward Capturing Treatments’ Improvement in Clinical Trials
por: Budimirovic, Dejan B., et al.
Publicado: (2022)

Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome
por: Chonchaiya, Weerasak, et al.
Publicado: (2010)

Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study
por: Brašić, James Robert, et al.
Publicado: (2022)

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents
por: Hagerman, Randi, et al.
Publicado: (2018)

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
por: Hagerman, Randi, et al.
Publicado: (2010)

Language across the Lifespan in Fragile X Syndrome: Characteristics and Considerations for Assessment
por: Hoffmann, Anne, et al.
Publicado: (2020)

Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation
por: Wang, Jun Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ma3s39h02ceqhjsauankod4pb6